www.onclive.com/. /Novartis-Plans-Acquisition-of-GSKs-Oncology- Products‎CachedApr 22, 2014 . GlaxoSmithKline (GSK) has agreed to sell its entire oncology portfolio to .

www.britishsarcomagroup.org.uk/updates/4569213887‎CachedThe BSG has been informed that pazopanib (Votrient from GSK) for advanced

www.msds-gsk.com/GetEraFile.ashx?fileId=29‎CachedSimilarJan 10, 2014 . GSK is committed to ensuring that our compounds do not adversely affect .

link.springer.com/article/10.1007%2Fs40278-013-4962-0Aug 10, 2013 . GlaxoSmithKline (GSK) is recommending that pazopanib [Votrient] recipients

www.gsk.com/. /results-from-phase-iii-patient-preference-study-of-gsk’s- votrient-pazopanib-vs-sutent-sunitinib-in-advanced-renal-cell-carcin. ‎CachedApr 1, 2014 . The primary objective of this study was to assess how the tolerability and safety

retinaresearchcenter.com/objects/GSK_2012.pdf‎Cached15mg oral pazopanib administered to neovascular AMD patients was .

www.pharmafile.com/news/101224/gsk-votrient-pazopanib-nice‎CachedSimilarDec 24, 2010 . NICE has recommended GlaxoSmithKline's kidney cancer drug Votrient in final

www.pharmaphorum.com/. /gsks-votrient-fails-in-ovarian-cancer‎CachedApr 1, 2014 . GSK's Votrient fails in ovarian cancer - News GlaxoSmithKline has withdrawn its

www.businesswire.com/. /Merck-Collaborates-GlaxoSmithKline-Evaluate- Combination-Regimen-Advanced‎CachedSimilarDec 18, 2013 . Pazopanib was approved by the US Food and Drug Administration for . and

https://www.gsksource.com/votrient‎CachedIn patients with pre-existing moderate hepatic impairment, the starting dose of

www.european-biotechnology-news.com/. /gsks-pazopanib-delays-kidney- cancer-progression.html‎CachedLondon – GlaxoSmithKline's anti-angiogenic treatment of kidney cancer,

www.ft.lk/2014/05/06/gsk-launches-votrient-in-sri-lanka/‎CachedMay 6, 2014 . GlaxoSmithKline (GSK) has announced the launch in Sri Lanka of Votrient (

www.fiercepharma.com/story/gsk-ditches. votrient/2014-04-01‎CachedSimilarApr 1, 2014 . Rafael Amado, GSK's head of oncology research and development, said in a

meetinglibrary.asco.org/content/131489-144‎CachedPazopanib in uterine sarcoma (UtS): Review of two European Organisation for

www.dailynews.lk/?q=business/gsk-launches-votrientr-sri-lanka‎CachedMay 6, 2014 . GlaxoSmithKline (GSK) has announced the launch in Sri Lanka of Votrient(r) (

hcp.gsk.co.uk/products/votrient.html‎CachedSimilarVotrient in advanced renal cell carinoma (RCC), pazopanib, product information,

www.thepharmaletter.com/. /merck-co-trialing-mk-3475-with-gsk-s- pazopanib-in-renal-cancer‎CachedDec 18, 2013 . US pharma giant Merck & Co (NYSE: MRK) says it has initiated a clinical trial to

www.reuters.com/. /us-novartis-cancer-drugs-idUSBREA3L0W120140422‎CachedApr 22, 2014 . ZURICH (Reuters) - Novartis believes GlaxoSmithKline's cancer drugs Votrient,

www.nice.org.uk/. /renal-cell-carcinoma-first-line-metastatic-pazopanib- manufacturers-response-to-nices-request-for-clarification2‎CachedAug 20, 2010 . In this setting GSK has chosen to conduct a trial comparing pazopanib to

www.rxwiki.com/clinical. /study-assess-long-term-safety-pazopanib‎CachedPurpose, This study is a rollover study to evaluate the long term safety of

article.wn.com/. /Results_from_phase_III_patient_preference_study_of_ GSK_s_Vot/‎CachedApr 1, 2014 . Head-to-head study of GSK's Votrient® (pazopanib) vs sunitinib in advanced

www.gsk.com/. /regulatory-update-votrient-pazopanib-as-maintenance- therapy-for-advanced-ovarian-cancer-in-the-eu/‎CachedMar 31, 2014 . GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that it has . for a

clinicaltrials.gov/show/NCT01235962‎CachedSimilarOct 14, 2010 . This randomized Phase III study is to evaluate whether pazopanib . Drug:

www.gskforyou.com/patient-assistance-programs/drugslist.html‎CachedSimilarGSK offers several patient assistance programs to help eligible individuals

www.kantarhealth.com/. /gsk-set-to-file-votrient-for-ovarian-cancer-on- strong-pfs.pdf?. ‎SimilarJun 3, 2013 . Nevertheless, GSK believes that the risk/benefit profile is good enough now to

www.moderntimeshelplinepharma.com/votrient-gsk-1848429.html‎CachedMODERN TIMES HELP LINE PHARMA - Exporter, Distributor & Supplier of

www.bloomberg.com/. /glaxo-pazopanib-as-effective-as-pfizer-drug-in- renal-cancer-1-.html‎CachedSimilarOct 1, 2012 . GlaxoSmithKline Plc (GSK)'s pazopanib pill for renal cell carcinoma . Glaxo

en.wikipedia.org/wiki/Pazopanib‎CachedSimilarPazopanib (trade name Votrient) is a potent and selective multi-targeted . See

www.pmlive.com/. /gsk_halts_bid_for_votrient_maintenance_use_557006‎CachedSimilarApr 1, 2014 . GlaxoSmithKline (GSK) has abandoned its bid to extend Votrient's . a positive

www.kidneycancercanada.ca/. /us-fda-approves-gsks-votrient-(pazopanib)- for-mrcc/‎CachedOct 20, 2009 . Votrient, a once-daily, oral medication, is an angiogenesis inhibitor which may

www.europeanpharmaceuticalreview.com/. /gsk-announces-late-stage- clinical-data-for-votrient-pazopanib-following-chemotherapy-in-wo. ‎CachedJun 1, 2013 . GSK announces late-stage clinical data for VOTRIENT® (pazopanib) following

www.pbs.gov.au/industry/listing/elements/pbac. /pazopanib.pdf;. ‎CachedNov 20, 2012 . Sponsor: Glaxo Smith Kline Australia Pty Ltd . This was the first submission for

www.medscape.com/viewarticle/812492‎CachedSimilarOct 11, 2013 . In a small trial, 15 mg oral pazopanib was well-tolerated and linked to

www.genengnews.com/gen-news. /merck. gsk. /81249265/‎CachedSimilarDec 18, 2013 . Joins GSK in Phase I/II Study of MK-3475 . Merck said it will evaluate the drug

www.ackc.org/kidney. pazopanib. /pazopanib-versus-placebo/‎CachedSimilarPazopanib is an oral angiogenic inhibitor that especially targets VEGEFR-1, .

www.gsk-clinicalstudyregister.com/compounds/pazopanib‎CachedSimilarGSK Clinical Study Register - Studies filtered by compound pazopanib. . Study

www.fda.gov/downloads/AdvisoryCommittees/. /UCM296303.pdf‎CachedSimilarMar 20, 2012 . Pazopanib, discovered and developed by GSK, is a tyrosine kinase inhibitor .

www.gskcta.com/‎CachedSimilarCommitment to Access is a portal to provide patients, Advocates, and healthcare

clinicaltrials.gov/show/NCT02014636‎CachedDec 12, 2013 . This is an open-label, 2 part study of pazopanib and/or MK 3475 in treatment . ..

www.thehindubusinessline.com/. /glaxosmithkline. /article2285697.ece‎CachedSimilarJul 22, 2011 . Revolade is priced at Rs. 27,000 a month and Votrient is priced at Rs. 58,000 a .

www.medpagetoday.com/HematologyOncology/. /41129‎CachedSimilarAug 22, 2013 . Pazopanib was noninferior to sunitinib with respect to progression-free survival

www.gsk.com.au/votrient‎CachedMay 16, 2014 . VOTRIENT is used to treat kidney cancer that is advanced or has spread to .

hcp.gsk.ie/products/votrient.html‎CachedSimilarVotrient™ is a trade mark of the GlaxoSmithKline group of companies. . events

www.fiercebiotech.com/story/glaxo-scraps. votrient/2014-03-31‎CachedMar 31, 2014 . GlaxoSmithKline ($GSK) is throwing in the towel on its campaign to get Votrient

www.pharmatimes.com/. /GSK_pulls_back_Votrient_for_ovarian_cancer. aspx‎CachedSimilarMar 31, 2014 . Patients with advanced ovarian cancer will be disappointed by news that

www.medicinesresources.nhs.uk/. /GSK%20press%20release.pdf‎CachedSimilarUK/PAZ/0114/13. July 2013. For medical media only. 10 July 2013, London, UK.

www.wlox.com/. /new-data-for-pazopanib-gsks-latest-investigational-anti- cancer-agent-shows-promise-across-multiple-cancersTwo Phase II studies demonstrated potential for pazopanib as a single agent

www.drugs.com/votrient.html‎CachedSimilarVotrient is used to treat renal cell carcinoma (kidney cancer). Learn about side

www.indiamart.com/moderntimes/pazopanib-tablets.html‎CachedExporter and Supplier of Pazopanib Tablets, Votreint Dose, Pazopanib, Votrient

www.gsk.ca/english/docs-pdf/product-monographs/Votrient.pdf‎CachedSimilarJan 30, 2014 . ®VOTRIENT is a registered trademark, used under license by GlaxoSmithKline

Sitemap